Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbro Linderholm

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Acta Oncologica (Stockholm, Sweden)|December 23, 2010
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancerSara Margolin, Nils-Olof Bengtsson, Lena Carlsson, et al.
International Journal of Cancer|December 18, 2024
Integration of personalised ultrasensitive ctDNA monitoring of patients with metastatic breast cancer to reduce imaging requirementsPia Mouhanna, Anders Ståhlberg, Daniel Andersson, et al.
Breast Cancer Research and Treatment|December 1, 2017
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancerAlexios Matikas, Sara Margolin, Mats Hellström, et al.
British Journal of Cancer|January 26, 2018
Immune gene expression and response to chemotherapy in advanced breast cancerTheodoros Foukakis, John Lövrot, Alexios Matikas, et al.
Medical Oncology (Northwood, London, England)|January 17, 2013
Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapyChikako Suzuki, Lennart Blomqvist, Thomas Hatschek, et al.
Breast (Edinburgh, Scotland)|April 26, 2017
The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?Matti Aapro, Michelino De Laurentiis, Dan Rea, et al.
BMJ Open|December 9, 2023
ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden-a phase III randomised double-blinded placebo-controlled studyKenny A Rodriguez-Wallberg, Hanna Pauline Nilsson, Jonas Bergh, et al.
Cancer Treatment Reviews|January 24, 2025
Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussionStavroula L Kastora, Eirini Pantiora, Yong Hwa Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2015
Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast CancerSiker Kimbung, Ida Johansson, Anna Danielsson, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2017
Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramMarijn A Vermeulen, Leen Slaets, Fatima Cardoso, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Acta Oncologica (Stockholm, Sweden)|December 23, 2010
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancerSara Margolin, Nils-Olof Bengtsson, Lena Carlsson, et al.
International Journal of Cancer|December 18, 2024
Integration of personalised ultrasensitive ctDNA monitoring of patients with metastatic breast cancer to reduce imaging requirementsPia Mouhanna, Anders Ståhlberg, Daniel Andersson, et al.
Breast Cancer Research and Treatment|December 1, 2017
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancerAlexios Matikas, Sara Margolin, Mats Hellström, et al.
British Journal of Cancer|January 26, 2018
Immune gene expression and response to chemotherapy in advanced breast cancerTheodoros Foukakis, John Lövrot, Alexios Matikas, et al.
Medical Oncology (Northwood, London, England)|January 17, 2013
Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapyChikako Suzuki, Lennart Blomqvist, Thomas Hatschek, et al.
Breast (Edinburgh, Scotland)|April 26, 2017
The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?Matti Aapro, Michelino De Laurentiis, Dan Rea, et al.
BMJ Open|December 9, 2023
ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden-a phase III randomised double-blinded placebo-controlled studyKenny A Rodriguez-Wallberg, Hanna Pauline Nilsson, Jonas Bergh, et al.
Cancer Treatment Reviews|January 24, 2025
Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussionStavroula L Kastora, Eirini Pantiora, Yong Hwa Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2015
Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast CancerSiker Kimbung, Ida Johansson, Anna Danielsson, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2017
Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramMarijn A Vermeulen, Leen Slaets, Fatima Cardoso, et al.
Pageof 5